Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Bullboard Posts
Comment by dmacdon Mar 19, 2019 2:17pm
51 Views
Post# 29506405

RE:RE:RepliCel Reignites its First-in-Japan Strategy

RE:RE:RepliCel Reignites its First-in-Japan Strategy I believe all of these plans will burn more than $5M hence there must be another plan forming to roll all of this out. I doubt it will be a dilutive financing or rather hope that it will be via motiviated partnership agreements with time limits to retain exclusive rights.

The plan is ambitious which is what folks wanted so I view this as a win and see what the rest of the plan looks like. I really appreciated the update since it reconfirms the near term path to progression of the product line. 

You can be certain that YOFOTO will be given an option to participate, and one would think they will take the option, and otherwise we will gain a new partner to share in the global R&D costs. 

The negotiations may take a few more months before a deal is finalized although before then we might see a LOI or MOU announced. 

I am not buying more shares until I see more progression on a business plan that is fully funded to get to the approvals stage. I have a core position though in case the SP runs but that will take an awesome deal and it is unclear if the product line is sufficiently advanced to warrant that. 

Perhaps the rights to other markets than Japan would open the flood gates to a big partnership with ambitious timelines to maintain these rights. We truly have nothing to lose with such a deal since go it alone is not viable in the current market. 

I am still optimistic that management will deliver on this path since this seems to be their strength. Shiseido and YOFOTO are proof in that regards and while we are not seeing the results yet we have good reason for hopeful outcomes from both of these partnerships. 


Bullboard Posts